scholarly journals LEFT AND RIGHT VENTRICULAR REMODELING IN PATIENTS WITH EARLY STAGE BREAST CANCER RECEIVING SEQUENTIAL ANTHRACYCLINE AND TRASTUZUMAB THERAPY - A CARDIAC MRI STUDY

2018 ◽  
Vol 34 (10) ◽  
pp. S179-S180
Author(s):  
M. Altaha ◽  
M. Nolan ◽  
E. Amir ◽  
K. Connelly ◽  
C. Brezden-Masley ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Right Ventricular ◽  
Cardiac Mri ◽  
Ventricular Remodeling ◽  
Early Stage ◽  
Early Stage Breast Cancer ◽  
Trastuzumab Therapy ◽  
Left And Right ◽  
Mri Study ◽  
Right Ventricular Remodeling

scholarly journals The Experience of a Multidisciplinary Clinic in the Management of Early-Stage Breast Cancer Patients Receiving Trastuzumab Therapy: An Observational Study

2012 ◽  
Vol 2012 ◽  
pp. 1-5 ◽  
Author(s):  
Susan Dent ◽  
Sean Hopkins ◽  
Nadine Graham ◽  
Christopher Johnson ◽  
Angeline Law ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Observational Study ◽  
Early Stage ◽  
Treatment Completion ◽  
Left Ventricular ◽  
Early Stage Breast Cancer ◽  
Left Ventricular Ejection ◽  
Trastuzumab Therapy ◽  
Cardiac Medication ◽  
The Impact

Background. We established a dedicated cardiac oncology clinic in 2008 for the rapid diagnosis and treatment of cardiotoxicity related to cancer therapy. In this retrospective observational study, we report on clinical outcomes in women with early-stage breast cancer (EBC) referred to this clinic.Methods. Patients with EBC treated with chemotherapy/trastuzumab and referred between October 2008 and December 2010. Data included patient demographics, staging, cancer treatment/completion, dose delays, left ventricular ejection fraction (LVEF) and cardiac treatment.Results. Forty eight patients: median age 55.5 years, stage I/II disease (77%) and HER-2 positive (98%). The majority of women (n=32) were referred for decreases in LVEF (from baseline). Overall, 37 (77%) patients experienced at least one drop in LVEF while on treatment, of which 22 patients (59%) experienced a ≥10 percentage point drop. The majority of patients (30/37; 81%) experienced declines in LVEF while on trastuzumab. Interventions included trastuzumab delays (n=16/48; 33%) and cardiac medication (12/48: 25%). A total of 81% of patients completed ≥90% of trastuzumab therapy and 15% of patients discontinued therapy due to cardiotoxicity.Conclusion. The majority of patients referred to our clinic completed therapy. Further studies are needed to determine the impact of this multidisciplinary approach on treatment completion and cardiac outcomes.

Sign in / Sign up

Export Citation Format

Share Document